Natera, Inc. (NASDAQ:NTRA) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Natera, Inc. (NASDAQ:NTRA) have earned an average recommendation of “Buy” from the eighteen research firms that are currently covering the stock, Marketbeat Ratings reports. Seventeen investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $194.00.

A number of research analysts have commented on the stock. Wall Street Zen downgraded shares of Natera from a “hold” rating to a “sell” rating in a research note on Saturday, May 17th. Cowen reiterated a “buy” rating on shares of Natera in a research note on Friday, August 8th. Royal Bank Of Canada set a $268.00 price objective on shares of Natera and gave the company an “outperform” rating in a research note on Tuesday, September 2nd. Morgan Stanley reiterated an “overweight” rating and set a $195.00 price objective on shares of Natera in a research note on Sunday, August 10th. Finally, Barclays reaffirmed an “overweight” rating and issued a $210.00 price objective (up previously from $190.00) on shares of Natera in a report on Friday, August 8th.

Insider Transactions at Natera

In other Natera news, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $166.77, for a total value of $500,310.00. Following the completion of the transaction, the insider owned 130,205 shares of the company’s stock, valued at $21,714,287.85. The trade was a 2.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Michael Burkes Brophy sold 3,045 shares of Natera stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $137.40, for a total transaction of $418,383.00. Following the completion of the transaction, the chief financial officer directly owned 65,430 shares of the company’s stock, valued at approximately $8,990,082. This represents a 4.45% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 56,423 shares of company stock valued at $8,459,656 over the last quarter. Insiders own 5.63% of the company’s stock.

Institutional Investors Weigh In On Natera

Hedge funds and other institutional investors have recently modified their holdings of the stock. LRI Investments LLC bought a new stake in shares of Natera during the fourth quarter valued at about $29,000. Bank of Jackson Hole Trust bought a new stake in shares of Natera during the first quarter valued at about $29,000. Rakuten Securities Inc. raised its stake in shares of Natera by 117.8% during the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 119 shares in the last quarter. ORG Partners LLC bought a new stake in shares of Natera during the first quarter valued at about $32,000. Finally, TCTC Holdings LLC raised its stake in shares of Natera by 114.8% during the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 124 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Natera Price Performance

NASDAQ NTRA opened at $176.37 on Friday. Natera has a 12 month low of $114.62 and a 12 month high of $183.00. The company has a market capitalization of $24.21 billion, a price-to-earnings ratio of -92.34 and a beta of 1.68. The company’s fifty day moving average price is $154.63 and its two-hundred day moving average price is $153.87.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The company had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. During the same quarter last year, the company earned ($0.30) earnings per share. The company’s revenue was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Natera will post -1.49 EPS for the current year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.